BofA Global Research cuts Axsome Therapeutics price objective to $264 from $276
AXSM•BofA Global Research cut its price objective for Axsome Therapeutics to $264 from $276.
Related News
Jefferies raises Vulcan Materials target price to $335 from $320
VMC•
Reddit blasts Australia's 'inept' social media ban as challenge airs in court
RDDT•
Tempus AI upgraded to hold from underperform; price target raised to $70 from $35
TEM•
Lonza agrees to buy five US CDMO sites from Merck
MRK•
CVR Energy reportedly nears more than $4 billion deal for Marathon refineries
MPC•